肽受体放射性核素治疗嗅觉神经母细胞瘤的生存结局。

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-09-01 DOI:10.21873/anticanres.17746

Hidenori Suzuki, Hiroya Taniguchi, Yoshitaka Inaba, Hiroyuki Tachibana, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai

{"title":"肽受体放射性核素治疗嗅觉神经母细胞瘤的生存结局。","authors":"Hidenori Suzuki, Hiroya Taniguchi, Yoshitaka Inaba, Hiroyuki Tachibana, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai","doi":"10.21873/anticanres.17746","DOIUrl":null,"url":null,"abstract":"Background/aim: Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.Patients and methods: Twenty-three patients with olfactory neuroblastoma who underwent initial definitive treatment from 1998 to 2023 were enrolled in this retrospective study.Results: Patients who underwent surgery were significantly associated with longer local recurrence-free survival from the initial definitive treatment compared to those who underwent radiotherapy. Among 18 patients with residual disease or first recurrence, those with distant metastasis related significantly with shorter overall survival from the diagnosis day of residual disease/first recurrence. Among 11 patients with unresectable multi-recurrent olfactory neuroblastoma, the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT.Conclusion: PRRT was associated with improved survival in patients with unresectable multi-recurrent olfactory neuroblastoma.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3877-3884"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Survival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.\",\"authors\":\"Hidenori Suzuki, Hiroya Taniguchi, Yoshitaka Inaba, Hiroyuki Tachibana, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai\",\"doi\":\"10.21873/anticanres.17746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/aim: Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.Patients and methods: Twenty-three patients with olfactory neuroblastoma who underwent initial definitive treatment from 1998 to 2023 were enrolled in this retrospective study.Results: Patients who underwent surgery were significantly associated with longer local recurrence-free survival from the initial definitive treatment compared to those who underwent radiotherapy. Among 18 patients with residual disease or first recurrence, those with distant metastasis related significantly with shorter overall survival from the diagnosis day of residual disease/first recurrence. Among 11 patients with unresectable multi-recurrent olfactory neuroblastoma, the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT.Conclusion: PRRT was associated with improved survival in patients with unresectable multi-recurrent olfactory neuroblastoma.\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 9\",\"pages\":\"3877-3884\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17746\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17746","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：嗅觉神经母细胞瘤伴不可切除的多次复发疾病的全身治疗尚不明确。然而，肽受体放射性核素治疗（PRRT）与177lu -戊特肽被认为是一种有效的全身治疗不可切除的多发复发的嗅觉神经母细胞瘤表达生长抑素受体。本研究探讨了嗅觉神经母细胞瘤的生存结果与治疗方式之间的关系，重点是肽受体放射性核素治疗。患者和方法：本回顾性研究纳入了1998年至2023年接受初始决定性治疗的23例嗅觉神经母细胞瘤患者。结果：与接受放射治疗的患者相比，接受手术的患者从最初的最终治疗开始的局部无复发生存期明显延长。在18例有残留病变或首次复发的患者中，有远处转移的患者自残留病变/首次复发诊断之日起总生存期明显缩短。在11例不可切除的多发复发性嗅神经母细胞瘤患者中，接受PRRT的3例患者自诊断时起的总生存期明显长于未接受PRRT的8例患者。结论：PRRT与不能切除的多发复发嗅神经母细胞瘤患者生存率提高相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Survival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.

Background/aim: Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.

Patients and methods: Twenty-three patients with olfactory neuroblastoma who underwent initial definitive treatment from 1998 to 2023 were enrolled in this retrospective study.

Results: Patients who underwent surgery were significantly associated with longer local recurrence-free survival from the initial definitive treatment compared to those who underwent radiotherapy. Among 18 patients with residual disease or first recurrence, those with distant metastasis related significantly with shorter overall survival from the diagnosis day of residual disease/first recurrence. Among 11 patients with unresectable multi-recurrent olfactory neuroblastoma, the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT.

Conclusion: PRRT was associated with improved survival in patients with unresectable multi-recurrent olfactory neuroblastoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.